Clene Inc. (CLNN)
NASDAQ: CLNN · Real-Time Price · USD
5.89
-0.36 (-5.76%)
Dec 29, 2025, 4:00 PM EST - Market closed
Clene Revenue
Clene had revenue of $15.00K in the quarter ending September 30, 2025, a decrease of -82.76%. This brings the company's revenue in the last twelve months to $214.00K, down -49.17% year-over-year. In the year 2024, Clene had annual revenue of $342.00K, down -47.71%.
Revenue (ttm)
$214.00K
Revenue Growth
-49.17%
P/S Ratio
255.02
Revenue / Employee
$2,816
Employees
76
Market Cap
60.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 342.00K | -312.00K | -47.71% |
| Dec 31, 2023 | 654.00K | 181.00K | 38.27% |
| Dec 31, 2022 | 473.00K | -250.00K | -34.58% |
| Dec 31, 2021 | 723.00K | 517.00K | 250.97% |
| Dec 31, 2020 | 206.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Walmart | 703.06B |
| Costco Wholesale | 280.39B |
| PepsiCo | 92.37B |
| The Procter & Gamble Company | 84.93B |
| Unilever | 70.19B |
| Anheuser-Busch InBev | 58.61B |
| The Coca-Cola Company | 47.66B |
| Philip Morris International | 39.99B |
CLNN News
- 20 days ago - Clene to Present at the Emerging Growth Conference - GlobeNewsWire
- 26 days ago - Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8® - GlobeNewsWire
- 27 days ago - Clene to Provide CNM-Au8® ALS Program Update - GlobeNewsWire
- 5 weeks ago - Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference - GlobeNewsWire
- 6 weeks ago - Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights - GlobeNewsWire
- 2 months ago - Clene to Participate in a Panel Discussion at the Maxim Growth Summit - GlobeNewsWire
- 3 months ago - Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients - GlobeNewsWire
- 4 months ago - Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease - GlobeNewsWire